11 . 02 .2026
Press release
Galderma expands Restylane® portfolio in Japan with launch of OBT™ hyaluronic acid injectables Restylane Defyne™ and Refyne™
02 . 02 .2026
Press release
Galderma announces U.S. FDA acceptance of RelabotulinumtoxinA Biologics License Application resubmission
30 . 01 .2026
Press release
Galderma tackles menopause-related skin changes with global survey and clinical trial inclusivity
29 . 01 .2026
Press release
Galderma unveils ‘Wake Up To Restylane’, underscoring Restylane as the ideal hyaluronic acid treatment for always-on natural beauty
22 . 01 .2026
Press release
IMCAS 2026: Galderma showcases the latest scientific advances behind the industry’s broadest injectable aesthetics portfolio
21 . 01 .2026
Press release
Galderma provides update on arbitration case regarding neuromodulator research and development partnership
14 . 01 .2026
Press release
TOXINS 2026: Clinical updates on Galderma’s leading neuromodulator portfolio further reinforce its leadership in Injectable Aesthetics
17 . 12 .2025
Press release
New published data confirms Nemluvio® (nemolizumab) can rapidly relieve itch and improve sleep in as early as two days in both atopic dermatitis and prurigo nodularis